Drugs / LIPO-5
LIPO-5
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials · 1 met primary | ||||||
| Phase 1/2 | NCT02038842 | Mar 2014 → Oct 2015 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | Met primary |
| Phase 1/2 | NCT00076063 | Mar 2004 → Mar 2007 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01492985 | Jul 2013 → Oct 2016 | HIV infectious disease | ANRS, Emerging Infectious Diseases | Completed | No outcome recorded |
| Phase 2 | NCT00121758 | Sep 2004 → Nov 2007 | HIV infectious disease | French National Agency for Research on AIDS and Viral Hepatitis | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LIPO-5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02038842 ↗ |
| Known as | ANRS LIPO-5 vaccine candidate | “ANRS LIPO-5 vaccine candidate” NCT02038842 ↗ |
| Known as | HIV LIPO-5 | “a boost vaccination with a lipopeptide vaccine (HIV-LIPO-5) in HIV-infected patients on combined antiretroviral therapy” PMID 33568510 ↗ Apr 20211“HIV LIPO-5 (five lipopeptides from Gag, Pol, Nef)” PMID 35613727 ↗ May 2022 |
| Modality | Vaccine | “The study was halted due to a case of myelitis possibly related to the LIPO-5 vaccine; this case of myelitis remains an isolated event.” PMID 25253665 ↗ Sep 2014 |
| Route | Intramuscular | “followed by a boost of LIPO-5 vaccine or placebo also given IM” NCT01492985 ↗ |